Huyabio signs clinical collaboration agreement for phase III melanoma trial of HBI-8000 with Opdivo March 31, 2021
Phase III trial of Xospata in relapsed or refractory AML with FLT3 mutation meets OS endpoint March 30, 2021
Conditional E.U. marketing authorization for Nexpovio in relapsed or refractory multiple myeloma March 30, 2021
European Commission approves Pemazyre for cholangiocarcinoma with FGFR2 fusion or rearrangement March 30, 2021
RSS